Pseudo-noncompetitive antagonism of muscarinic receptor-mediated cyclic GMP formation and phosphoinositide hydrolysis by pirenzepine

E. E. El-Fakahany, W. Surichamorn, C. L. Amrhein, S. Stenstrom, C. L. Cioffi, E. Richelson, M. McKinney

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Pirenzepine selectively antagonized muscarinic receptor-mediated cyclic GMP formation in a noncompetitive fashion in mouse neuroblastoma cells (clone N1E-115). These effects of pirenzepine were time- and concentration-dependent and they were also reversible. Interestingly, whereas atropine elicited competitive antagonism of the cyclic GMP response at low concentrations, it also behaved like a noncompetitive antagonist at higher concentrations and its effects were partially reversible. Using additional approaches to study the mechanisms underlying this anomalous antagonistic profile of pirenzepine, we investigated whether this deviation from competition could be due to the short time of exposure to muscarinic agonists (30 sec) used in cyclic GMP measurements. Our data indicated that the mode of pirenzepine-induced antagonism of ligand binding to muscarinic receptors was different when assessed using nonequilibrium (30 sec) or equilibrium (1 hr) incubations. Thus, pirenzepine appeared to be noncompetitive and competitive under these two conditions, respectively. Furthermore, although pirenzepine blocked receptor-mediated phosphoinositide hydrolysis competitively when the response was measured at 20 min, it was clearly noncompetitive using 5-min incubations. Therefore, the noncompetitive antagonism by pirenzepine detected in cyclic GMP measurements might be only apparent and might be attributed at least in part, to a lack of an equilibrium state under the specific conditions of these assays.

Original languageEnglish (US)
Pages (from-to)934-940
Number of pages7
JournalJournal of Pharmacology and Experimental Therapeutics
Volume247
Issue number3
StatePublished - 1988
Externally publishedYes

Fingerprint

Pirenzepine
Cyclic GMP
Muscarinic Receptors
Phosphatidylinositols
Hydrolysis
Muscarinic Agonists
Neuroblastoma
Atropine
Clone Cells
Ligands

ASJC Scopus subject areas

  • Pharmacology

Cite this

El-Fakahany, E. E., Surichamorn, W., Amrhein, C. L., Stenstrom, S., Cioffi, C. L., Richelson, E., & McKinney, M. (1988). Pseudo-noncompetitive antagonism of muscarinic receptor-mediated cyclic GMP formation and phosphoinositide hydrolysis by pirenzepine. Journal of Pharmacology and Experimental Therapeutics, 247(3), 934-940.

Pseudo-noncompetitive antagonism of muscarinic receptor-mediated cyclic GMP formation and phosphoinositide hydrolysis by pirenzepine. / El-Fakahany, E. E.; Surichamorn, W.; Amrhein, C. L.; Stenstrom, S.; Cioffi, C. L.; Richelson, E.; McKinney, M.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 247, No. 3, 1988, p. 934-940.

Research output: Contribution to journalArticle

El-Fakahany, EE, Surichamorn, W, Amrhein, CL, Stenstrom, S, Cioffi, CL, Richelson, E & McKinney, M 1988, 'Pseudo-noncompetitive antagonism of muscarinic receptor-mediated cyclic GMP formation and phosphoinositide hydrolysis by pirenzepine', Journal of Pharmacology and Experimental Therapeutics, vol. 247, no. 3, pp. 934-940.
El-Fakahany, E. E. ; Surichamorn, W. ; Amrhein, C. L. ; Stenstrom, S. ; Cioffi, C. L. ; Richelson, E. ; McKinney, M. / Pseudo-noncompetitive antagonism of muscarinic receptor-mediated cyclic GMP formation and phosphoinositide hydrolysis by pirenzepine. In: Journal of Pharmacology and Experimental Therapeutics. 1988 ; Vol. 247, No. 3. pp. 934-940.
@article{90027c72baeb4c769b6bcb25f6f7a1ca,
title = "Pseudo-noncompetitive antagonism of muscarinic receptor-mediated cyclic GMP formation and phosphoinositide hydrolysis by pirenzepine",
abstract = "Pirenzepine selectively antagonized muscarinic receptor-mediated cyclic GMP formation in a noncompetitive fashion in mouse neuroblastoma cells (clone N1E-115). These effects of pirenzepine were time- and concentration-dependent and they were also reversible. Interestingly, whereas atropine elicited competitive antagonism of the cyclic GMP response at low concentrations, it also behaved like a noncompetitive antagonist at higher concentrations and its effects were partially reversible. Using additional approaches to study the mechanisms underlying this anomalous antagonistic profile of pirenzepine, we investigated whether this deviation from competition could be due to the short time of exposure to muscarinic agonists (30 sec) used in cyclic GMP measurements. Our data indicated that the mode of pirenzepine-induced antagonism of ligand binding to muscarinic receptors was different when assessed using nonequilibrium (30 sec) or equilibrium (1 hr) incubations. Thus, pirenzepine appeared to be noncompetitive and competitive under these two conditions, respectively. Furthermore, although pirenzepine blocked receptor-mediated phosphoinositide hydrolysis competitively when the response was measured at 20 min, it was clearly noncompetitive using 5-min incubations. Therefore, the noncompetitive antagonism by pirenzepine detected in cyclic GMP measurements might be only apparent and might be attributed at least in part, to a lack of an equilibrium state under the specific conditions of these assays.",
author = "El-Fakahany, {E. E.} and W. Surichamorn and Amrhein, {C. L.} and S. Stenstrom and Cioffi, {C. L.} and E. Richelson and M. McKinney",
year = "1988",
language = "English (US)",
volume = "247",
pages = "934--940",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Pseudo-noncompetitive antagonism of muscarinic receptor-mediated cyclic GMP formation and phosphoinositide hydrolysis by pirenzepine

AU - El-Fakahany, E. E.

AU - Surichamorn, W.

AU - Amrhein, C. L.

AU - Stenstrom, S.

AU - Cioffi, C. L.

AU - Richelson, E.

AU - McKinney, M.

PY - 1988

Y1 - 1988

N2 - Pirenzepine selectively antagonized muscarinic receptor-mediated cyclic GMP formation in a noncompetitive fashion in mouse neuroblastoma cells (clone N1E-115). These effects of pirenzepine were time- and concentration-dependent and they were also reversible. Interestingly, whereas atropine elicited competitive antagonism of the cyclic GMP response at low concentrations, it also behaved like a noncompetitive antagonist at higher concentrations and its effects were partially reversible. Using additional approaches to study the mechanisms underlying this anomalous antagonistic profile of pirenzepine, we investigated whether this deviation from competition could be due to the short time of exposure to muscarinic agonists (30 sec) used in cyclic GMP measurements. Our data indicated that the mode of pirenzepine-induced antagonism of ligand binding to muscarinic receptors was different when assessed using nonequilibrium (30 sec) or equilibrium (1 hr) incubations. Thus, pirenzepine appeared to be noncompetitive and competitive under these two conditions, respectively. Furthermore, although pirenzepine blocked receptor-mediated phosphoinositide hydrolysis competitively when the response was measured at 20 min, it was clearly noncompetitive using 5-min incubations. Therefore, the noncompetitive antagonism by pirenzepine detected in cyclic GMP measurements might be only apparent and might be attributed at least in part, to a lack of an equilibrium state under the specific conditions of these assays.

AB - Pirenzepine selectively antagonized muscarinic receptor-mediated cyclic GMP formation in a noncompetitive fashion in mouse neuroblastoma cells (clone N1E-115). These effects of pirenzepine were time- and concentration-dependent and they were also reversible. Interestingly, whereas atropine elicited competitive antagonism of the cyclic GMP response at low concentrations, it also behaved like a noncompetitive antagonist at higher concentrations and its effects were partially reversible. Using additional approaches to study the mechanisms underlying this anomalous antagonistic profile of pirenzepine, we investigated whether this deviation from competition could be due to the short time of exposure to muscarinic agonists (30 sec) used in cyclic GMP measurements. Our data indicated that the mode of pirenzepine-induced antagonism of ligand binding to muscarinic receptors was different when assessed using nonequilibrium (30 sec) or equilibrium (1 hr) incubations. Thus, pirenzepine appeared to be noncompetitive and competitive under these two conditions, respectively. Furthermore, although pirenzepine blocked receptor-mediated phosphoinositide hydrolysis competitively when the response was measured at 20 min, it was clearly noncompetitive using 5-min incubations. Therefore, the noncompetitive antagonism by pirenzepine detected in cyclic GMP measurements might be only apparent and might be attributed at least in part, to a lack of an equilibrium state under the specific conditions of these assays.

UR - http://www.scopus.com/inward/record.url?scp=0024213082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024213082&partnerID=8YFLogxK

M3 - Article

VL - 247

SP - 934

EP - 940

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -